Integrative Molecular Phenotyping
INTEGRATIVE MOLECULAR
PHENOTYPING
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY

KI News

Updated: 1 hour 30 min ago

Professor Staffan Normark awarded the Robert Koch Gold Medal

Fri, 27/04/2018 - 11:06
Staffan Normark, senior professor at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet, has been awarded the Robert Koch Gold Medal. He receives the medal for lifetime achievements as a biomedical researcher and mentor, and specifically for his research into microorganisms such as viruses, bacteria and fungi and their ability to cause disease. Professor Staffan Normark is a successful, prize-winning, leading international researcher in the field of molecular microbiology who has also worked tirelessly to support the activities and careers of young researchers so that they in turn can successfully initiate and conduct their own high-quality research. The medal will be presented at an official ceremony at the Berlin-Brandenburg Academy of Sciences and Humanities on 16 November 2018. In 1998, this same medal was awarded to Georg Klein, professor emeritus in tumour biology at Karolinska Institutet until his death in 2016. The Robert Koch Foundation is a non-profit foundation that supports research in the field of infectious diseases, as well as exemplary projects designed to address medical and hygienic problems. The medal is named after doctor and researcher Robert Koch (1843 – 1910) who laid the foundations for modern bacteriology, discovered the bacterium responsible for tuberculosis and was awarded the Nobel Prize in Physiology or Medicine in 1905.

KI's Vice-Chancellor: "Universities important actors in global health work"

Wed, 25/04/2018 - 12:06
The importance of collaboration was a recurring theme when the Swedish Global Health Research Conference was held at Karolinska Institutet on 18–19 April. Over the course of two days, the attendees investigated how their research and commitment to global health can contribute to achieving the goals of the 2030 Agenda for Sustainable Development. The aim of the conference is to reinforce interdisciplinary research into global health and Sweden and to show how Sweden is able to contribute to achieving the global sustainability goals stated in the UN 2030 Agenda. Karolinska Institutet’s Vice-Chancellor, Ole Petter Ottersen, opened the conference by emphasising the important role students – the leaders of the future – have to play in achieving the goals of the 2030 Agenda. He stated that universities are very important stakeholders in this work and that new study programmes are needed that meet the major challenges presented by the sustainable development goals. “Because the task is so complex, the universities must take particular responsibility. And the complexity must be reflected in our study programmes to a much greater degree than is presently the case,” says Ole Petter Ottersen. Aims to reach the general public with information from the UN The other opening speaker at the conference, Ola Rosling, who founded the Gapminder Foundation together with his father, Hans Rosling, professor of international health, who died last year, and his wife Anna Rosling. The foundation works to spread knowledge about the situation in the world by developing new tools with which to visualise statistics. In one project, Gapminder has asked questions about global development to the general public in fourteen countries. One of the questions is “What proportion of the world’s one-year-olds are vaccinated against any disease?”, with the responses available being 20, 50 or 80 per cent. In Sweden, 22 per cent of those asked answered correctly, which is a worse result than would have been generated by choosing randomly. “We see there is a lot of ignorance and are trying to find new ways to reach the general public with information from the UN,” says Ola Rosling. He noted that the correct answer is 80 per cent, and now even higher.   The questions were also asked to certain smaller groups, for example attendees at the World Health Summit in Berlin in 2017. Twenty-seven per cent of that group answered the vaccination question correctly. “These experts are therefore largely ignorant about the major successes achieved by vaccination programmes. Even fewer of the investors at one of the world’s largest banks answered correctly. In a world that is changing, these adults have an inaccurate world-view and don’t know what the world they are investing in looks like,” he says. At the conference at Karolinska Institutet, 84 per cent of attendees answered the vaccination question correctly. Research, data and expertise make decision making easier The conference’s first panel discussion covered the challenges and opportunities in the field of global health, with the 2030 Agenda forming the backdrop. Agnes Binagwaho, Vice-Chancellor of the University of Global Health Equity in Rwanda and the country’s former health minister, stated that all parts of the world can make a contribution to global health. She described how the African region has reduced infant mortality faster than other parts of the world, but that more is required and believes Sweden can contribute to the sustainable development goals by prioritising making research, data and expertise available in order to make it easier to introduce data-driven decision making. Ernest Aryeetey, General-Secretary of the African Research Universities Alliance, stated that global health is a global concern and must be treated as such, and also that collaboration between different scientific disciplines is required. “The future requires us to collaborate across disciplinary boundaries and between universities. No single discipline has all the answers – if we are to develop new treatments and demonstrate that they work as intended, collaboration is required between doctors, engineers, sociologists, economists and behavioural scientists, for example,” says Ernest Aryeetey. The importance of collaboration was emphasised by many speakers, for example in Wednesday’s panel discussion, which dealt with needs and opportunities for research within global health. It was observed that Sweden, as a small country, has a great deal of experience collaborating outside of the country and is able to build on this. "Sweden must dare to use its loud voice" Kristina Gemzell, professor of obstetrics and gynaecology at Karolinska Institutet, stated that Sweden has a loud voice internationally, which we must dare to use in order to achieve the sustainable development goals. “I work in an area that is often hidden away – women’s access to safe, high-quality abortions. Sweden must dare to use its loud voice when we talk about sexual and reproductive health. We must dare to mention abortions, support research in this area and bridge the gap between research and policy,” said Kristina Gemzell. The attendees were then divided into smaller groups in order to discuss tangible issues in a workshop setting. The second day of the conference was about making the move from research to implementation and discussed successful examples of this. This year’s edition was the third time the Swedish Global Health Research Conference has been held. It was organised by the Swedish Society of Medicine in partnership with representatives of all seven Swedish medical faculties, as well as Familjen Einhorns stiftelse, the Government Offices of Sweden and the Swedish Institute for Global Health Transformation (SIGHT). The conference was hosted by the Department of Public Health Sciences at Karolinska Institutet. Text: Sara Nilsson Foto: Erik Cronberg

Hello there … Knut Lönnroth, head of KI’s new TB research centre

Wed, 25/04/2018 - 11:20
Hello there Knut Lönnroth, professor at the Department of Public Health Sciences and director of KI’s new TB research centre ... why has KI set up a TB centre? “Tuberculosis is one of the most prevalent communicable diseases in the world and the new centre has been set up to contribute to the development of better diagnostics, vaccines and treatments. The centre will also conduct research in the fields of epidemiology and healthcare organisation and on how to design and provide social and financial support for patients. Sufficient social support is particularly important for people with TB, since most of them are poor." “We also want to strengthen the collaborative ties between the departments concerned as well as the university’s national and international standing in TB research. The global TB situation is only very slowly improving, and the death rate is still very high, with 5,000 deaths a day. KI’s new TB centre is also a response to the fact that the WHO has raised the bar for research to expedite this trend and attain the goals laid out in the UN’s Agenda 2030.” How is it being funded? “The centre has been set up by five KI departments, but its administrative base is the Department of Public Health Sciences. Each research group is separately financed but we also are very hopeful that we can apply for more funding jointly. So far, the centre has received SEK 50,000 in start-up grant from the Board of Research and as much again from the Department of Public Health Sciences.” How will it lead to advancement? “For many years we’ve had a great deal to offer at KI when it comes to TB-related research, in disciplines ranging from immunology, biochemistry and microbiology to public health and health economics. The centre will allow us to reinforce this research, to do more relevant research, tie together research teams, coordinate research training and encourage even stronger interest for collaboration with KI." “We also want to work with information and lobbying. Despite the global political support, many politicians need to be convinced to invest more. Another dilemma is that it’s hard from a market perspective to get investors to back research since poor people have a low payment capacity.” Text: Helena Mayer

Imagined and real movements are controlled by the brain in the same way

Tue, 24/04/2018 - 11:18
A new study from Karolinska Institutet shows that imagined movements can change our perception in the same way as real, executed movements do. The research, which is presented in the scientific journal Nature Communications, contributes to an increased understanding of how mental training works and may be useful for patients with motor disabilities. “Mental training is very beneficial if you want to improve your motor performance – this is something elite athletes and professional musicians know very well. We wanted to find out the mechanisms behind this phenomenon,” says Dr. Konstantina Kilteni, lead author of the study and researcher at Karolinska Institutet’s Department of Neuroscience. Touch resulting from our voluntary movements, for example when we touch one hand with the other, feels less intense compared to when somebody else touches our hand with the exact same intensity. This is because our brain uses information about how we plan to move in order to predict how we will feel. These predictable sensations feel weaker. The brain predicts how we would feel “Our study shows that if we imagine the movement but we do not physically perform it, real touch will still feel less intense,” says Dr. Kilteni. “This implies that during imagining the movement the brain also predicts how we would feel if the imagined movements were executed. Taken together our findings suggest that imagined and real movements have very similar brain mechanisms, if not sharing the same one, which may explain the positive effects of mental training”. The study consists of three series of experiments where 36 healthy individuals were asked to either perform or imagine performing a movement. The experimenters recorded muscular activity to ensure that the participants were not moving while imagining. During imagination, the participants were told to imagine pressing their right index finger against the relaxed left index finger. At the same time, a touch was applied on their left index finger via specially designed equipment. Participants perceived this touch as less intense compared to when they were neither moving nor imagining suggesting that the brain had predicted how they would feel. In fact, their weakened perception during imagination was equivalent to that when they physically performed the movement. May be useful for some patient groups In addition to shedding new light on a classic question in psychology and neuroscience – whether the brain’s representation of imagined and executed movements are the same – the results can be useful for clinical research, especially for neurological patient groups with motor disabilities. “For example, stroke patients imagining performing the movement that they cannot physically perform could benefit their motor rehabilitation,” says principal investigator Dr. H. Henrik Ehrsson, professor at Karolinska Institutet’s Department of Neuroscience. “Another area of application concerns paralysed or amputated patients that use brain-computer interfaces to control artificial limbs through imagining moving them.” The study was funded by the European Commission, the Swedish Research Council, the Torsten Söderberg Foundation and Riksbankens Jubileumsfond. Publication “Motor imagery involves predicting the sensory consequences of the imagined movement” Konstantina Kilteni, Benjamin Jan Andersson, Christian Houborg and H. Henrik Ehrsson Nature Communications, online 24 April 2018, doi: 10.1038/s41467-018-03989-0

No increased risk of recurrence in breast cancer after reconstruction with abdominal tissue

Mon, 23/04/2018 - 12:51
After surgery for breast cancer women who have undergone breast reconstruction using abdominal tissue do not have a higher risk of recurrence than women who do not undergo breast reconstruction. This has been shown by researchers at Karolinska Institutet in a study published in the British Journal of Surgery. In Sweden today, more than 90,000 women are living with a diagnosis of breast cancer, and each year almost 2,000 women die from the disease. More than 90 per cent undergo surgery for their breast cancer. Reconstruction can be performed if the entire breast is removed, using either an implant or tissue from the woman’s own body. Today, many women want to reconstruct their breast using tissue from themselves. This tissue can be taken from the abdomen and transplanted to the site of the breast that has been removed. This particular and common method is called DIEP flap reconstruction, which stands for deep inferior epigastric artery perforator flap reconstruction. Physical trauma “Discussions have been ongoing for some time as to whether this type of reconstruction is safe or whether it could contribute to a higher risk of recurrence. Previous studies had given conflicting results”, says Hannah Adam, PhD Candidate at the Department of Molecular Medicine and Surgery at Karolinska Institutet, and the first author of a new study that examines the risk of recurrence. The operation, which takes several hours, is a physical trauma that could theoretically result in an impaired immune system and reactivation of dormant micrometastases. The current study included 254 patients who all underwent surgery using the DIEP flap method at Karolinska University Hospital Solna 1999-2013. Each patient was matched with up to three patients in a control group including 729 patients, all of whom had removed a breast without any secondary reconstructive surgery. No increased risk The results revealed that slightly less than 20 per cent of the women in the DIEP group versus 24 per cent in the control group had recurrence of breast cancer at follow-up after seven or six years. The five-year survival rate after surgery was 92 per cent and slightly less than 90 per cent respectively. “Our study demonstrates that there is no increased risk of recurrence for women who undergo this type of reconstruction. Moreover, the survival rate was higher for the DIEP group than the control group”, says Hannah Adam. The study is financed by the Percy Falk Foundation, the Swedish Society for Medical Research, Stockholm County Council and the Karolinska Institutet. Publication “Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction” H Adam, AC Docherty Skogh, Å Edsander Nord, I Schultz, J Gahm, P. Hall, J Frisell, M Halle and J de Boniface British Journal of Surgery, online 23 April 2018, doi:10.1002/bjs.10866

Aggressive breast cancer has resistant tumour cells already prior to chemotherapy

Thu, 19/04/2018 - 18:01
Difficult to treat and aggressive “triple-negative” breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center reports. The findings, which are published in the journal Cell, may lead to better and more personalised treatments for breast cancer. Breast cancer is the most common form of cancer in women and the most common cause of death in middle-aged women in Sweden. Triple-negative breast cancer (TNBC) is an aggressive and difficult to treat form of the disease that makes up about 15 per cent of all breast cancer cases. Chemotherapy is the cornerstone of treatment for TNBC, used either prior to surgery or prophylactically after surgery, as well as for treatment of metastatic disease. Even though several chemotherapy drugs are effective against TNBC, resistance to treatment is a common problem since it can ultimately lead to relapse and tumour growth. For many years researchers have been trying to understand why such resistance develops and to prevent or reverse it. Key question “A key question is whether the resistance develops because of the existence of resistant groups of cells, called clones, in the tumour from the start, or whether tumour cells develop new genetic changes (mutations) during the treatment that cause resistance,” says Theodoros Foukakis, Associate Professor at the Department of Oncology-Pathology, Karolinska Institutet, who co-led the study with Associate Professor Nicholas Navin at the University of Texas MD Anderson Cancer Center, Houston, USA. The researchers analysed tumour tissue from 20 patients with TNBC who received preoperative chemotherapy. The tissue was collected before the onset of therapy, after two courses of therapy and on surgery. The researchers used a technique called single-cell sequencing to examine the DNA and gene expression (RNA) of all genes in the individual tumour cells and thus ascertain the cells’ properties and kinship. “The DNA analyses revealed tumour clones remaining after treatment in half of the cases,” says Dr Foukakis. “When we studied them in detail at a single-cell level, we found that these same clones were present in the tumour before chemotherapy, often as a small minority of the tumour cell population.” Adapted their gene expression Single-cell RNA sequencing of thousands of cell nuclei showed that the remaining tumour clones had also adapted their gene expression during treatment to become even more chemoresistant. “All in all, the study shows that chemoresistance in TNBC is a complex process involving both a selection of resistant clones that existed in the tumour from the start as well as a reprogramming of their gene expression to ensure survival during therapy,” concludes Dr Foukakis. The results may provide a basis for future studies to identify therapy-resistant tumour clones and thus personalise treatment for breast cancer patients who respond poorly to chemotherapy and have a worse prognosis. The Swedish part of the study was financed by the Swedish Cancer Society, the Cancer Research Funds of Radiumhemmet and StratCan (KI-MDACC Collaborative Grants). The clinical study was part-financed by Roche, the Cancer Research Funds of Radiumhemmet and the Swedish Breast Cancer Association. Publication “Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single Cell Sequencing” Charissa Kim & Ruli Gao, Emi Sei, Rachel Brandt, Johan Hartman, Thomas Hatschek, Nicola Crosetto, Theodoros Foukakis and Nicholas Navin Cell, online 19 April 2018, doi: 10.1016/j.cell.2018.03.041

KI researchers awarded grants from the Swedish Childhood Cancer Foundation

Thu, 19/04/2018 - 08:49
Ten researchers at Karolinska Institutet have been awarded grants in the Swedish Childhood Cancer Foundation’s latest call for funding, during which approximately SEK 62 million was allocated. Appropriations include a six-year researcher position and several postdoctoral positions. Karolinska Institutet researchers account for 11 of 26 successful applications. Financing for a six-year senior research position was awarded to Lisa Westerberg of the Department of Microbiology, Tumor and Cell Biology for a project studying the link between the ability of antibodies to move around and an increased risk for childhood cancer. The aim of the study is to better understand how an uncontrolled immune response leads to immunodeficiency diseases and tumours in children. Magdalini Lourda of the Department of Women’s and Children’s Health has been granted funding for a research assistant position relating to immunological and genetic studies of children suffering from the rare condition Langerhans cell histiocytosis. The call also resulted in a grant to five KI researchers for postdoctoral positions. These are Saeed Eshtad, Aida Rodriguez Garcia, Jenny Thorsell Cederberg, Johanna Viiliäinen and Arnika Wagner. Doctoral grants for clinicians were awarded to Susanna Ranta and Emma Tham. Funding for clinical research months – three months per year for three years – was awarded to Bianca Tesi and Emma Tham. In total, approximately SEK 62 million in grants were awarded. From a total of 107 applications, 26 were granted – 17 of which came from women and 9 from men. The Swedish Childhood Cancer Foundation awards grants three times a year.

KI researcher Mandus Frykman appointed national coordinator

Thu, 19/04/2018 - 08:46
The Swedish Government has appointed Mandus Frykman, researcher at Karolinska Institutet, as national coordinator for a well-functioning sick-leave process. This newly established function involves examining how sick leave can be developed from an individual perspective. “I am extremely pleased and proud to be given this assignment. It is incredibly exciting and an opportunity to participate in influencing matters on a large scale,” says Mandus Frykman, a researcher at Karolinska Institutet’s Department of Learning, Informatics, Management and Ethics (LIME). Focus on the individual On 12 April, the Swedish Government appointed Mandus Frykman as national coordinator for the sick-leave process, a newly established function. At the same time, an inquiry was set up into health insurance and both of these initiatives are part of the action programme for health insurance presented by the Swedish Government earlier this year. Mandus Frykman’s research deals with the impact of decisions at board-room level on occupational health and safety. He is a psychologist and economist and is also works in occupational healthcare. As national coordinator, Mandus Frykman will be examining how the sick-leave process works and how it can be developed from an individual perspective. According to the Government, this is a matter of taking the individual’s journey through health insurance as a starting point and placing it at the centre of the process. Several stakeholders in cooperation Because the sick-leave process involves a number of stakeholders – such as employers, healthcare and welfare services, the Swedish Social Insurance Agency and the Swedish Public Employment Service – cooperation is a central concept. “Cooperation between stakeholders in the sick-leave process has proved to be a challenge, and my task is to analyse the preconditions for and promote cooperation between them. I look forward to getting started on the assignment and establishing contacts with the stakeholders and other experts in the field,” says Mandus Frykman. According to Minister for Health and Social Affairs Annika Strandhäll, both Magnus Frykman and Claes Jansson, responsible for the inquiry into health insurance, have a clear mandate to drive development towards a secure and modernised national health insurance. Mandus Frykman is due to deliver an interim report on his assignment on 30 April 2019, with a final report to be published no later than 30 April 2020.

The first occupational therapists and physiotherapists with a Master’s Degree in Dementia Care receive their diploma

Wed, 18/04/2018 - 10:34
Sweden’s first occupational therapists and physiotherapists with a Master’s in Dementia Care will be awarded their diploma today in the presence of HM Queen Silvia at a ceremony at the Royal Palace in Stockholm. The Master's Courses in Dementia Care is part of the efforts being made to improve theoretical and practical competence in the field of dementia care. The Master's Courses in Dementia Care were created four years ago as a joint undertaking by Karolinska Institutet and Silviahemmet. It is the only education of its kind, and has recently been expanded to include occupational therapists and physiotherapists as well as physicians. “It’s extremely gratifying that the first intake of occupational therapists and physiotherapists have now taken their Master’s in Dementia Care and that they will be receiving a diploma as ‘Silvia Occupational Therapists’ and ‘Silvia Physiotherapists’,” says Maria Eriksdotter, head of the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet. “Raising the educational bar for dementia diseases is in keeping with the recently updated national guidelines for dementia care and the government’s aims.” A total of fourteen participants have now completed this round of the Master's Courses in Dementia Care. Among the participants, one of the new degree recipients is the first physician from China to adopt the title of ‘Silvia Doctor’. The care of dementia sufferers has been in focus recently. At the end of last year, the National Board of Health and Welfare issued updated national guidelines for the health and social care of people with dementia, and in mid March this year, the government ringfenced additional funds for raising the quality of dementia care.

Study on fever in children in Africa may change global guidelines

Wed, 18/04/2018 - 06:00
Children in sub-Saharan Africa with uncomplicated fever may be safely managed with conditional, rather than universal, 3-day follow-up with a community health worker, according to a randomised trial by researchers at Karolinska Institutet published in PLOS Medicine. The study suggests that current WHO guidelines for these children could be reconsidered. The WHO’s integrated community case management (iCCM) guidelines recommend that all children presenting with uncomplicated fever and no danger signs return for follow-up with a community health worker on day 3 following the initial consultation on day 1. Such fevers often resolve rapidly, however, and previous studies suggest that expectant home care for uncomplicated fever can be safely recommended. The trial was conducted in Ethiopia and included approximately 4,000 children under age five with uncomplicated fever, who were randomised to receive either conditional follow-up if symptoms remained or the recommended universal 3-day follow up. The results suggest that conditional follow-up is non-inferior to universal follow-up. More efficient use of resources  “Allowing community health workers to advise caregivers to bring children back only in case of continued symptoms might be a more efficient use of resources in these settings,” says first author Karin Källander, adjunct senior lecturer at Karolinska Institutet’s Department of Public Health Sciences. Another study from Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States, published at the same time in PLOS Medicine, shows similar results for children in the Democratic Republic of the Congo (DRC). Additional trials in other sub-Saharan African settings are needed to establish generalisability. However, taken together, the current results provide evidence relevant to formulation of WHO recommendations. The study involving researchers from Karolinska Institutet was made possible by the support of the U.S. President's Malaria Initiative under the United States Agency for International Development's Translating Research into Action (TRAction) Project. This news article is based on a press release from PLOS Medicine. Publication “Universal versus conditional day 3 follow-up for children with non-severe unclassified fever at the community level in Ethiopia: A cluster-randomised non-inferiority trial” Källander K, Alfvén T, Funk T, Abebe A, Hailemariam A, Getachew D, Petzold M, Steinhardt LC, Gutman JR PLOS Medicine, online 17 April 2018, doi: 10.1371/journal.pmed.1002553

New disease model to facilitate development of ALS and MS drugs

Mon, 16/04/2018 - 17:03
Researchers at Karolinska Institutet have developed a new disease model for neurodegenerative diseases such as ALS and MS that can be used to develop new immunotherapies. The model is described in a publication in the scientific journal Nature Immunology. All of the body’s organs contain macrophages, which, as part of the immune system, consume bacteria and other foreign bodies. However, macrophages are also specialised according to the organ in which they operate; in the brain they are known as microglia, and researchers believe that this specialisation is controlled by the cytokine TGF-β, which is a kind of protein.  Involved in interneuronal communication In a healthy brain, microglia are involved in interneuronal communication and the renewal of myelin, the insulating sheaths enveloping axons of nerve cells that enable the transmission of nerve impulses. In diseases like MS and ALS, other immune cells called monocytes can enter the brain via the blood, be transformed into inflammatory cells and cause damage to the neurons and the myelin sheath. The researchers behind the current study had a hypothesis that TGF-β may program monocytes from being inflammatory cells to becoming microglia-like cells. “We already knew that TGF-β is produced in the brain and is important for giving microglia their specialised functions,” says first author Harald Lund, doctoral student at the Department of Clinical Neuroscience, Karolinska Institutet. “So we figured that monocytes should also respond to TGF-β when they enter the brain. We were curious to see what would happen if the monocytes lost the ability to respond to TGF-β.” Developed a disease similar to ALS To test this, the researchers first used a mouse model in which the animal’s own microglia could be removed. This lead to a rapid influx of monocytes into the brain and spinal cord, which gave rise to new microglia-like cells, and the mice displayed no pathological symptoms. But when the researchers then switched off the TGF-β receptors on the new microglia-like cells, they started to consume large parts of the myelin in the spinal cord. The mice quickly developed a deadly neurodegenerative disease, the symptoms of which were similar to those of ALS. The disease model can explain a mechanism that is active in neuroinflammatory and neurodegenerative diseases, and could be used to develop and test new immunotherapies. Today there are no effective treatments. Lack of experimental models “There are many deadly neurodegenerative diseases in humans, but a lack of experimental models for developing new immunotherapies,” says Professor Bob Harris at the Centre for Molecular Medicine, Karolinska University Hospital and the Department of Clinical Neuroscience, Karolinska Institutet. “This new disease model will be a valuable addition to our research programme and we hope that the next study will result in a new, effective therapy.” The study was financed by the Swedish Alzheimer’s Foundation, the Swedish Research Council, the Swedish Childhood Cancer Foundation, the Åke Wiberg Foundation, the Swedish MS Research Foundation, the NIH-NINDS, NIH-NIA, the National Multiple Sclerosis Society, the Amyotrophic Lateral Sclerosis Association, the Swedish Heart and Lung Foundation, the Novo Nordisk Foundation and the Margaretha af Ugglas Foundation. Publication “Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-β signaling” Lund H, Pieber M, Parsa R, Grommisch D, Ewing E, Kular L, Han J, Zhu K, Nijssen J, Hedlund E, Needhamsen M, Ruhrmann S, Ortlieb Guerreiro Cacais A, Berglund R, Forteza MJ, Ketelhuth DFJ, Butovsky O, Jagodic M, Zhang X-M, Harris RA Nature Immunology, online 16 April 2018, doi: 10.1038/s41590-018-0091-5

Conference on Global Health gathers researchers and students from the country’s institutes of higher learning

Mon, 16/04/2018 - 13:43
Sustainable development and global health is receiving a great deal of attention at Karolinska Institutet this week. Now, it is time to stop talking and start acting, states Tobias Alfvén, one of the organizers behind The Swedish Global Health Research Conference 2018, being held on April 18-19. What is this conference about? “It is based on the goals of the 2030 Agenda for Sustainable Development that the countries of the world have committed to attaining. It is something that is receiving increasing attention; but currently, there is more talk than action. A great deal of research is being done in Sweden that is relevant to these issues and addresses global health and other areas. But, working independently, each of us at our own country’s institutes of higher learning, is insufficient if we want to make a global difference; that demands collaborative thinking and working. The objective of the conference is to act as a forum for researchers, students and others who want to find a way to contribute.” What kind of conference is it? “We want the conference to be as rewarding as possible, and therefore, feel that there needs to be more than just lectures, even if such can be excellent and inspiring. Thus, more than half of the conference is being given to workshops for smaller groups, where the participants can take the opportunity to discuss specific issues.” Can you give a few examples? “Each participant will be able to reflect on how they, themselves, can contribute to the sustainability goals in terms of their own research or involvement, as well as the challenges that surround the next step, such as getting funding for their research or managing ethical issues. Another group of workshops is based on different research themes, such as pediatric health, safe abortions and antibiotic resistance.” How much interest is there, in the conference? “There will be twice as many participants as we first expected, so interest has exceeded all of our expectations. We are seeing an especially strong response from students throughout Sweden, which is gratifying. I think this reflects a general growing interest for the bigger issues. Many believe that contributions arising solely from their own specializations are insufficient and instead are seeking a broader perspective, which requires getting together and exchanging thoughts and experiences.” What do you hope the participants will take away from the conference? “That they will, even more clearly, realize and know how they can participate in and contribute to the 2030 Agenda. Text: Ola Danielsson

New mutation behind heart failure identified

Thu, 12/04/2018 - 07:00
An international research team involving Karolinska Institutet has identified a new mutation in South Asians that, in combination with a known mutation in the same gene, increases the risk of cardiomyopathy and heart failure. The finding, published in the scientific journal JAMA Cardiology, can lead to improved treatment options for a large number of patients. Four per cent of South Asians, around 100 million individuals, carry a deletion in a gene called MYBPC3. This deletion is known to be associated with an increased risk for cardiomyopathy and heart failure, but to varying degrees. An international team of researchers therefore aimed to find out if there are additional genetic variants that account for this risk variability. By analysing a South Asian population in the US, they found that 10 per cent of the people carrying the MYBPC3 deletion had an additional MYBPC3 mutation. This combination of mutations was linked to clinical findings that increase the risk of heart disease. The results have important implications for personalised healthcare and precision medicine. 10 million people “Our results indicate that around 10 million people worldwide carry the newly found mutation and that it most likely drives the initially described heart failure phenotype observed in patients with a MYBPC3 deletion. This subpopulation of patients are expected to benefit from new, tailored drugs focusing on mutations in the MYBPC3 gene,” says Ralph Knöll, adjunct professor at the Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (ICMC) at Karolinska Institutet's Department of Medicine, Huddinge. The study involved researchers from Karolinska Institutet, AstraZeneca, the University of Cincinnati, and National Heart Research Institute Singapore, among others. The research was funded by the American Heart Association Cardiovascular Genome-Phenome Study, AstraZeneca, Inc., the National Institutes of Health (NIH), the National Research Foundation Singapore, the National Medical Research Council in Singapore, Goh Foundation/Duke-NUS Graduate Medical School, SingHealth Foundation, Biomedical Research Council Singapore, Fondation LeDucq, Deutsche Forschungsgemeinschaft, and the Swedish Heart-Lung Foundation. Publication “Association of Cardiomyopathy With MYBPC3 D389V And MYBPC3Δ25bp Intronic Deletion in South Asian Descendants” Shiv Kumar Viswanathan, Megan J. Puckelwartz, Ashish Mehta, Chrishan J.A. Ramachandra, Aravindakshan Jagadeesan, Regina Fritsche-Danielson, Ratan V. Bhat, Philip Wong, Sangeetha Kandoi, Jennifer A. Schwanekamp, Gina Kuffel, Lorenzo L. Pesce, Michael J. Zilliox, Nalla B. Durai, Rama Shanker Verma, Robert E. Molokie, Domodhar P. Suresh, Philip R. Khoury, Annie Thomas, Thriveni Sanagala, Hak Chiaw Tang, Richard C. Becker, Ralph Knöll, Winston Shim, Elizabeth M. McNally, and Sakthivel Sadayappan JAMA Cardiology, online 11 April 2018, doi: 10.1001/jamacardio.2018.0618

KI researchers awarded the ERC AdG

Fri, 06/04/2018 - 12:05
Two researchers at Karolinska Institutet have been awarded the ERC Advanced Grant (AdG) 2017 from the European Research Council. The two researchers who receive this prestigious award are Henrik Ehrsson and Gunilla Karlsson Hedestam. In total, the ERC allocates funding to 269 European research projects, which is about 12% of all applicants. Henrik Ehrsson Principal investigator: Henrik Ehrsson, Professor of Cognitive Neuroscience, Department of Neuroscience Project: The Unity of the Bodily Self (SELF-UNITY) Application area: Social Sciences and Humanities A characteristic feature of human consciousness is the experience of oneself as a unified single body. Henrik Ehrsson studies the neuronal and behavioral principles that create this experience – how it is uphold under normal conditions and how it can be altered in different ways. In the project currently funded by the ERC, he will try to find out how information from our different senses – such as balance and feelings about the inner state of the body (interoception) – can work together to give us the feeling of a unique bodily self. The identification of the central neurocognitive mechanisms behind this feeling of having one single body would be regarded as true scientific breakthrough. In addition, Henrik Ehrsson hopes that his research will eventually contribute to better treatments for disorders with disturbances in self-unity, such as schizophrenia and stroke with body neglect. More about Henrik Ehrsson’s research Gunilla Karlsson Hedestam Principal investigator: Gunilla Karlsson Hedestam, Professor of Vaccine Research, Department of Microbiology, Tumor and Cell Biology microbiology Project: Defining human adaptive immune gene diversity and its impact on disease (IMMUNDIVERSITY) Application area: Life Sciences Why do people respond differently to infections and vaccination? Why do some people develop immune-associated diseases? We know that adaptive immunity plays a critical role in health management, but little is known about how inherited variations in the genes responsible for antigen recognition influence our bodies' immune responses. To answer these questions, Gunilla Karlsson Hedestam and her research team will explore human adaptive immune gene diversity and its impact on disease, using novel technology and processes. To enable future research in this area, the team will develop robust protocols that allow the analysis of adaptive immune receptor genes from large cohorts of individuals. The project will result in the creation of individualised immune receptor germline gene databases representing thousands of individuals, as well as freely accessible software tools for analysis of immune repertoire data that can be used by other researchers. More about Gunilla Karlsson Hedestam’s research ERC Advanced Grants in numbers Applications 2017 in total: 2167 Granted applications: 269 Of which in Life Sciences: 83 In Social Sciences and Humanities: 60 Granted applications in Sweden: 10 Total women grantees: 47 (17.5%) Source: ERC

Genetic link to IBS identified in women

Fri, 06/04/2018 - 09:15
New research coordinated from Karolinska Institutet links certain DNA variants to increased risk of irritable bowel syndrome (IBS) in women. The findings, published in the scientific journal Gastroenterology, might help explain why IBS is more common in women than in men. Irritable bowel syndrome is the most common gastrointestinal disorder. More than 10 per cent of the population, women more than men, suffer from recurrent symptoms including abdominal pain, gas, diarrhoea and constipation. What causes IBS is largely unknown, which hampers the development of effective treatment for many patients. Genetic predisposition to IBS is recognised, although poorly investigated. Now an international research team led by scientists from Karolinska Institutet in Sweden have identified DNA variants that are associated with increased risk of IBS, but only in women. Region linked to puberty timing “Exploiting the large UK Biobank resource, as well as several patient cohorts from European and US expert centres, we have been able to study genetic predisposition to IBS with increased statistical power, better than ever before,” says corresponding author Mauro D’Amato, visiting professor at Karolinska Institutet’s Department of Medicine in Solna and coordinator of the bellygenes initiative that led to the discovery. The researchers used genotype data from more than 300,000 UK Biobank participants in a genome-wide association study (GWAS). They found DNA variants that associate with increased risk of a doctor’s diagnosis of IBS in women but not in men, specifically from a region on chromosome 9 previously reported to also influence puberty timing in women (age at first menstruation). By following up this result in 2,045 patients from IBS expert centres in Sweden, Belgium, the Netherlands, Italy and the US, the researchers observed further associations with constipation-predominant IBS as well as harder stools, again only in women. Sex-hormones could play a role “Although we cannot point to individual genes at this early stage, we believe these results are exciting, as they converge with existing data on female preponderance and a role of sex-hormones in IBS,” says Mauro D’Amato. In addition to Karolinska Institutet, researchers and clinicians from several other institutions participated in the study, including the Mayo Clinic and University of California Los Angeles in the US, IKMB in Kiel Germany, TARGID in Leuven Belgium, BioDonostia HRI in San Sebastian Spain, the Universities of Bologna in Italy, Groningen and Maastricht in the Netherlands, and others. The research was supported by grants from the Swedish Research Council, the Health Department of the Basque Government, the Spanish Ministry of Economy and Competitiveness (ISCIII), the National Institutes of Health (NIH), and the EU FP7 (BBMRI-LPC), among others. Publication “Female-specific Association Between Variants on Chromosome 9 and Self-reported Diagnosis of Irritable Bowel Syndrome” Bonfiglio F, Zheng T, Garcia-Etxebarria K, Hadizadeh F, Bujanda L, Bresso F, Agreus L, Andreasson A, Dlugosz A, Lindberg G, Schmidt PT, Karling P, Ohlsson B, Simren M, Walter W, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Portincasa P, Bellini M, Barbara G, Latiano A, Hübenthal M, Thijs V, Netea MG, Jonkers D, Chang L, Mayer EA, Wouters MM, Boeckxstaens G, Camilleri M, Franke A, Zhernakova A, D’Amato M Gastroenterology, online 4 April 2018, doi: 10.1053/j.gastro.2018.03.064

PCSK9 inhibitors have unexpected anti-inflammatory effects

Thu, 05/04/2018 - 09:08
PCSK9 inhibition is a new therapeutic strategy for atherosclerosis which is known to lower LDL cholesterol. Research from Karolinska Institutet, presented at the ESC Congress last year and now published in the Journal of Internal Medicine, shows that PCSK9 inhibitors could ameliorate cardiovascular disease by immune mechanisms that are independent of LDL lowering. Atherosclerosis is a chronic inflammatory process involving cells of the immune system such as T cells and dendritic cells. Lipid-lowering statins are commonly used to treat the condition, and in recent years a new class of atherosclerosis drugs which inhibit the enzyme PCSK9 (proprotein convertase subtilisin kexin 9) has reached the marked. PCSK9 is known to target the LDL receptor, resulting in increased levels of low-density lipoprotein (LDL). Researchers at Karolinska Institutet have examined how immune cells from human atherosclerotic plaques are affected by PCSK9. Using a new experimental system, they found that oxidised LDL, a central player in atherosclerosis, induced PCSK9 and promoted the maturation of dendritic cells. These dendritic cells then mediated the activation of T cells into a pro-inflammatory phenotype. PCSK9 inhibition reversed the effects of oxidised LDL on immune activation. Could be anti-atherosclerotic “This anti-inflammatory effect was unexpected and could potentially be anti-atherosclerotic, suggesting that the benefits of PCSK9 inhibition extend beyond lowering LDL cholesterol,” says lead author Johan Frostegård, Professor at the Institute of Environmental Medicine, Karolinska Institutet. The study was funded by the Swedish Heart-Lung Foundation, the Swedish Research Council, the Stockholm County Council (ALF), the King Gustaf V 80th Birthday Fund, the Swedish Rheumatism Association, Vinnova, AFA Insurance, and Torsten Söderberg Foundation. The authors declare no conflict of interests. Publication “PCSK9 plays a novel immunological role in the oxidized LDL-induced dendritic cell maturation and T-cell activation from human blood and atherosclerotic plaque” Anquan Liu, Johan Frostegård Journal of Internal Medicine, online 4 April 2018, doi: 10.1111/joim.12758

Eva Hellström-Lindberg appointed Wallenberg Clinical Scholar 2018

Wed, 04/04/2018 - 09:32
KI researcher Eva Hellström-Lindberg has been appointed Wallenberg Clinical Scholar 2018, as one out of four researchers. She is granted SEK 15 million to build upon the discovery of a genetic change that is associated with a better disease prognosis of MDS, a form of blood cancer, and develop treatments. Wallenberg Clinical Scholars is part of the SEK 2.5 billion that the Knut and Alice Wallenberg Foundation is investing to boost medical research and the life sciences, Life Science. During the program period, 2015-2025, 25 grants will be awarded to Sweden's foremost clinical researchers. Each researcher is receiving SEK 15 million for a five-year period, with the potential for a five-year extension. Universities with medical faculties are invited to nominate researchers for these research grants and The Royal Swedish Academy of Sciences is responsible for the scientific evaluation. “Sweden has exceptionally good conditions for world-leading clinical research, but it has become increasingly difficult to combine research with the current pressured healthcare system. It is therefore very pleasing that the Knut and Alice Wallenberg Foundation is making such a significant investment and providing some of our most outstanding clinical researchers with such excellent resources. This is a great benefit, both for medical research and for Swedish healthcare,” says Göran K. Hansson, Secretary General of the Academy of Sciences, in a press release. Significantly improved the treatment of blood cancer Eva Hellström-Lindberg, chief physician and professor at the Department of Medicine, Huddinge, Karolinska Institutet, conducts research that has significantly improved the treatment of myelodysplastic syndrome (MDS), a form of blood cancer. Her objectives include being able to predict relapses following a bone marrow transplant, so as to save the lives of even more affected patients. Early treatment of a relapse increases the chance of being able to save the patient’s life. As a Wallenberg Clinical Scholar, Eva Hellström-Lindberg will build upon the discovery of a genetic change that is associated with a better disease prognosis, and develop treatments that can make the disease take a benign course.

Study shows how muscles regulate their oxygen consumption

Tue, 03/04/2018 - 18:00
A new study by researchers from Karolinska Institutet shows that an enzyme called FIH determines how muscles consume oxygen. Without the enzyme, the need for oxygen increases during physical exercise. The finding is of potential significance to elite athletes, who have been found to have higher levels of FIH in their muscles than others. The study is published in the esteemed scientific journal Cell Metabolism. When you exercise, your muscles consume oxygen to produce energy, until the level of oxygen drops below a particular threshold. Subsequently, energy is generated by the process of anaerobic metabolism, which does not require oxygen. However, this leads to the production of lactic acid and eventually exhaustion and cramping. In a new study, researchers demonstrate that the enzyme FIH (Factor Inhibiting HIF) is a key to how this switch-over happens. Precise regulation “We’ve discovered that the muscles regulate oxygen consumption in a very precise way using the oxygen-sensitive enzyme FIH,” says principle investigator Professor Randall Johnson at the Department of Cell and Molecular Biology, Karolinska Institutet. “The enzyme makes sure that the muscles can use a more effective oxygen-based metabolism for as long as possible and then promotes a very quick transition to anaerobic metabolism.” Using mice in which the production of the enzyme was blocked, the researchers found that mice lacking FIH in their muscles require more oxygen than normal when exercising. “We were able to show that without FIH, the muscles use much more oxygen than is otherwise the case,” says Professor Johnson. “This could be of great significance to elite athletes, who, according to an earlier study of ours, have uncommonly high levels of muscular FIH.” Present in all cells and tissues FIH was discovered over ten years ago, but until now no one has understood its exact function. FIH is found in all the body’s cells and tissues, but is 50 to 100 times more abundant in the muscles than in any other part of the body. The findings can now open the way for new forms of metabolism-affecting drugs. “No one’s entertained the idea of developing a drug that affects FIH before, but I think our study will lead to greater examination of that possibility,” says Professor Johnson. “Here you’re able to affect the metabolism itself, perhaps mainly in the muscles, but possibly in other parts of the body too. This can be important in other contexts, such as diabetes and obesity.” The study was conducted in Professor Randall Johnson’s laboratory at Karolinska Institutet, Sweden, and the University of Cambridge, England, and was financed by the Wellcome Trust, the Swedish Research Council, the Swedish Cancer Society and the Swedish Childhood Cancer Foundation. Publication ”The FIH (Factor Inhibiting HIF) asparaginyl hydroxylase regulates oxidative metabolism and accelerates metabolic adaptation to hypoxia” Jingwei Sim, Andrew S. Cowburn, Asis Palazon, Basetti Madhu, Petros A. Tyrakis, David Macías, David M. Bargiela, Sandra Pietsch, Michael Gralla, Colin E. Evans, Thaksaon Kittipassorn, Yu Chinn Joshua Chey, Cristina M. Branco, Helene Rundqvist, Daniel J. Peet, and Randall S. Johnson Cell Metabolism, online 3 April 2018, doi: 10.1016/j.cmet.2018.02.020

Collaboration provides clinical research of the highest quality

Thu, 29/03/2018 - 13:57
A report from the Swedish Research Council shows that the clinical research conducted in collaboration between Karolinska Institutet (KI) and Stockholm County Council (SLL) maintains a very high level of quality. The Swedish Research Council has evaluated clinical research conducted at those county councils that are signatories to what is known as the ALF Agreement, an agreement between the Swedish Government and certain county councils regarding collaboration on educating doctors, conducting clinical research and developing healthcare. The evaluation was based on three different categories; the quality of clinical research, the clinical significance and social benefits of research, and the preconditions for the research. “We will of course be studying the Swedish Research Council’s report in greater detail, but I can confirm that it demonstrates that the scientific quality of clinical research at KI-SLL is very high. The evaluation also points to a high level of quality in terms of the research’s clinical significance, social benefits and the preconditions. This is most gratifying and an acknowledgment of the fantastic job our staff are doing and that our collaboration with SLL is working well,” comments Ole Petter Ottersen, vice-chancellor of Karolinska Institutet. The evaluation was carried out by three external and independent panels appointed by the Swedish Research Council after a nominations process. “One area for improvement is our joint work on implementation, this is to say, our ability to translate our clinical research into practical healthcare applications so that it can really create value for patients. In cooperation with SLL, this will be a priority going forward. We need more research regarding how research results are implemented in healthcare,” says Ole Petter Ottersen. From 2019, a new allocation model will be introduced for ALF funding, the state’s reimbursement for county councils’ undertaking to participate in training doctors and conducting clinical research. This model will mean that 20% of research funding will be allocated based on an evaluation of the quality of clinical research. The Swedish Research Council’s evaluation provides the basis for this allocation. “I would like to emphasis that, in and of itself, our participation in the evaluation has provided us with a great many valuable new insights,” says Ole Petter Ottersen. In parallel with the Swedish Research Council’s evaluation, the Swedish National Board of Health and Welfare has been undertaking a government assignment to evaluate university hospital care. The National Board of Health and Welfare’s report points out that quality is generally good, although there are also areas for improvement here.  

Internationalisation the theme for KI’s Educational Congress

Fri, 23/03/2018 - 12:56
Karolinska Institutet’s biennial Educational Congress took place on 15-16 March. The main focus of this year’s congress was on medical educational research and the internationalisation of education. Leading researchers in both of these fields participated, as well as the Chair of the Swedish Government Inquiry on increased internationalisation of higher education institutions.  “Higher education must be considered equally as important as research and it is not possible to attain high levels of quality in education without internationalisation,” said vice-chancellor Ole Petter Ottersen on opening the congress. Karolinska Institutet’s Educational Congress is a biennial initiative to improve competences among the university’s educators. The main focus of this year’s congress was on medical educational research and internationalisation. “We want to support and encourage teachers in their pedagogical activities and provide opportunities for an exchange of knowledge among educators at KI. We have found ourselves one step ahead in the internationalisation of education, however, we now need to move forward,” said Annika Östman Wernerson, dean of higher education. Internationalisation must permeate everything One of the congress’ opening speakers was Betty Leask, emeritus professor at La Trobe University, Melbourne, Australia and author of the book Internationalizing the Curriculum. She spoke about the importance of widening the concept of internationalisation. It is not simply a matter of mobility, courses in English and the number of international students. Internationalisation is an attitude that must permeate all activities. It includes intercultural competence, globalisation and openness – and should be a component of learning objectives. According to Betty Leask, universities should be educating professional citizens who are flexible, innovative and open to new ideas, making them better professionals in meetings with patients. “The quality of education is raised by focusing on internationalisation at home. And these measures must be purposeful, planned and aimed at all students and teachers, not only those who will be travelling abroad,” said Betty Leask. National strategy for all higher education institutions Agneta Bladh is the Swedish Government’s special investigator and chair of their internationalisation inquiry. Her role includes proposing both a new national strategy for the internationalisation of higher education institutions in Sweden, and how students can gain an international perspective in their education. At the congress, she presented her recently delivered summary report, Internationalisation of Swedish Higher Education and Research – A Strategic Agenda. “Swedish higher education institutions must be able to establish themselves abroad, and overseas stakeholders must have the opportunity to establish themselves in Sweden. International experience should be considered a merit and we need to include ethical perspectives in international collaborations,” said Agneta Bladh. Prize-winner among keynote speakers Another keynote speaker was Brian Hodges, professor at the University of Toronto, Canada and recipient of KI’s 2016 Prize for Research in Medical Education. He spoke about how technological developments are opening the way for new professional roles in healthcare and that technical solutions can free-up more time for patient contact and empathy. He also mentioned the importance of understanding the limits of artificial intelligence and that this perspective should be included in study programmes. Today, pedagogical development is about ensuring that students will be able to execute their future professional roles, but also develop as people and be equipped to participate in a multilingual and international labour market. Several speakers pointed out that the goal of KI’s study programmes is not merely to prepare students for their future professions in medicine and health, but also to be good citizens of an increasingly global society.  The Educational Congress is organised by the Centre for Learning and Knowledge on behalf of KI’s Board of Higher Education, this year in collaboration with the Gunnar Höglund and Anna-Stina Malmborg Foundation. Text: Sabina Bossi and Sabina Giulini

Pages